Basel, Basel, Switzerland
GENERAL MANAGER, DEAL CLOSER, and CORPORATE STRATEGIST. I've led teams to: • Deliver finance, human resources, strategy, and fundraising capabilities for a biotech start-up • Deliver sales and profit growth on a $500+ million P&L • Execute $7 billion of M&A transactions, including a new biologics CDMO manufacturing site and business in China • Create value through strategy and innovation at life sciences companies Management consultant and U.S. military officer background. I'm open to new professional connections via LinkedIn. If I don't know you, please include a brief note stating why you think we should connect.
Leading the corporate and business functions of CPTx (cptx.bio). CPTx is a preclinical-stage biotechnology company developing non-viral, duration-tunable in vivo CAR T cell therapies. We are advancing immune-quiet single-stranded DNA vectors with broad potential in cancer, autoimmune disorders, and beyond, leveraging the ability to enable durable responses, tune expression from transient to permanent, and deliver multiple genes at once. Based in Munich, Germany and in San Francisco, CA, our team brings together deep expertise in DNA vector design, genetic engineering, cancer and immune cell biology.
Delivered above-market top- and bottom-line growth on annual sales of >$500 million to global generics and vaccines manufacturers. • Grew sales volume and value both during and after COVID-19 pandemic, with profitability growing ahead of sales • Led, built, and developed a global cross-functional commercial team of ~25 West colleagues and more than 100 external agent & distributor partners • Championed integrated business planning reforms to improve prioritization, automation, and planning processes in order to improve customer service
Expanded Lonza’s biologics contract development and manufacturing organization services into China. Closed three-party deal with GE Healthcare, Guangzhou Development District, and Lonza to create Lonza’s first biomanufacturing facility and business in China.
Led strategic portfolio management to improve biologics manufacturing medicines with disposable technologies, continuous processes, digitization, and new business models.
Senior legacy-Novartis Vaccines leader in GSK Vaccines integration office responsible for implementing the transition / integration for global functions and >50 country organizations.
Vaccines division’s chief strategist and M&A project team leader, reporting to the Executive Committee. Took two deals from signing to closing: • $5.3B sale of non-influenza vaccines business to GSK, part of ground-breaking 3-part transaction between Novartis and GSK (2015) • $1.7B sale of Novartis’s blood transfusion diagnostics unit to Grifols (2014)
General manager for all in-country activities for oncology products in hematology, solid tumors and rare cancers. Grew P&L to $28M revenue by leading a team of ~25. Exceeded sales and operating profit targets, achieving ca. 10% p.a. growth in a flat/declining market. Met clinical development and medical affairs targets.
Field-based sales role selling to doctors and other health care professionals: $2M sales at 9 primary hospital accounts; achieved first reimbursed UK sales of Afinitor.